Pheochromocytoma adjunct therapy

Pheochromocytoma adjunct therapy refers to the use of supplementary pharmacological agents alongside primary surgical resection or foundational alpha-adrenergic blockade in patients with catecholamine-secreting neuroendocrine tumors of the adrenal medulla These tumors arise from chromaffin tissue and provoke excessive sympathetic stimulation, presenting clinically with paroxysmal or sustained hypertension, episodic headaches, palpitations, and diaphoresis

Pheochromocytoma adjunct therapy refers to the use of supplementary pharmacological agents alongside primary surgical resection or foundational alpha-adrenergic blockade in patients with catecholamine-secreting neuroendocrine tumors of the adrenal medulla In this clinical context, adjunctive therapy typically targets cardiovascular hemodynamic instability—such as tachyarrhythmias or refractory hypertension—using secondary agents like beta-blockers, calcium channel blockers, or catecholamine synt...

These tumors arise from chromaffin tissue and provoke excessive sympathetic stimulation, presenting clinically with paroxysmal or sustained hypertension, episodic headaches, palpitations, and diaphoresis

In this clinical context, adjunctive therapy typically targets cardiovascular hemodynamic instability—such as tachyarrhythmias or refractory hypertension—using secondary agents like beta-blockers, calcium channel blockers, or catecholamine synthesis inhibitors once foundational blockade is established, or serves to manage inoperable, metastatic, or residual disease